Risk of hypertension with regorafenib in cancer patients: a systematic review and meta-analysis

By Wang Zexing   Xu Jing   Nie Weiwei   Huang Guichun   Tang Jinhai   Guan Xiaoxiang  

European Journal of Clinical Pharmacology, Vol. 70, Iss. 2, 2014-02 ,pp. : 225-231

Springer Publishing Company

Access to resources Recommend Favorite

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan

By Vincenzi Bruno   Santini Daniele   Russo Antonio   Gavasci Michele   Battistoni Fabrizio   Dicuonzo Giordano   Rocci Laura   Rosaria Valerio Maria   Gebbia Nicola   Tonini Giuseppe  

Pharmacogenomics, Vol. 8, Iss. 4, 2007-04 ,pp. : 319-327

Future Medicine

Access to resources Recommend Favorite

Risk of Hepatic Events in Patients Treated with Vancomycin in Clinical Studies: A Systematic Review and Meta-Analysis

By Chen Yan   >   Zeckel Michael   Killian Chris   Hornbuckle Kenneth   Regev Arie   Voss Simon  

Drug Safety, Vol. 34, Iss. 1, 2011-01 ,pp. : 73-82

Adis International

Access to resources Recommend Favorite

Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBs: A Systematic Review and Meta-Analysis

By Khalaf Mohamad M. Al  

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 1, 2009-01 ,pp. : 29-43

Adis International

Access to resources Recommend Favorite

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan

By Hoskins Janelle M   Rosner Gary L   Ratain Mark J   McLeod Howard L   Innocenti Federico  

Pharmacogenomics, Vol. 10, Iss. 7, 2009-07 ,pp. : 1139-1146

Future Medicine

Access to resources Recommend Favorite